Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline Review, H1 2020’, provides an overview of the Granulomatosis with Polyangiitis (Wegener's Granulomatosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

– The report reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener's Granulomatosis) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Granulomatosis with Polyangiitis (Wegener's Granulomatosis) therapeutics and enlists all their major and minor projects

– The report assesses Granulomatosis with Polyangiitis (Wegener's Granulomatosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener's Granulomatosis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biogen Inc

Bristol-Myers Squibb Co

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxis

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Overview

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Companies Involved in Therapeutics Development

Biogen Inc

Bristol-Myers Squibb Co

ChemoCentryx Inc

Generium

GlaxoSmithKline Plc

Humanigen Inc

iBio Inc

InflaRx NV

Insmed Inc

Nichi-Iko Pharmaceutical Co Ltd

Pharmapraxis

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Drug Profiles

abatacept – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INS-1007 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biobetter – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Dormant Projects

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Discontinued Products

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Product Development Milestones

Featured News & Press Releases

Jan 30, 2020: The CHMP recommended extensions of indication for MabThera

Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication

Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders

May 16, 2019: GSK presents Nucala at ATS 2019

Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US

Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in final guidance

Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis

Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera

Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Biogen Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Bristol-Myers Squibb Co, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by ChemoCentryx Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Generium, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by GlaxoSmithKline Plc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Humanigen Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by iBio Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by InflaRx NV, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Insmed Inc, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Pipeline by Pharmapraxis, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Dormant Projects, H1 2020

Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener's Granulomatosis), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports